

CCDC134 Antibody - C-terminal region
Rabbit Polyclonal Antibody
Catalog # AI15482**Specification****CCDC134 Antibody - C-terminal region - Product Information**

Application	WB
Primary Accession	Q9H6E4
Other Accession	NM_024821 , NP_079097
Reactivity	Human, Mouse, Rat, Rabbit, Horse, Bovine, Guinea Pig, Dog
Predicted	Human, Mouse, Rat, Rabbit, Pig, Horse, Bovine, Guinea Pig, Dog
Host	Rabbit
Clonality	Polyclonal
Calculated MW	25kDa KDa

CCDC134 Antibody - C-terminal region - Additional Information**Gene ID 79879****Alias Symbol** [FLJ22349](#), [MGC21013](#), [dJ821D11.3](#)**Other Names**

Coiled-coil domain-containing protein 134, CCDC134

Format

Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.

Reconstitution & Storage

Add 50 ul of distilled water. Final anti-CCDC134 antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles.

Precautions

CCDC134 Antibody - C-terminal region is for research use only and not for use in diagnostic or therapeutic procedures.

CCDC134 Antibody - C-terminal region - Protein Information

Name CCDC134 {ECO:0000303|PubMed:39509507, ECO:0000312|HGNC:HGNC:26185}

Function

Molecular adapter required to prevent protein hyperglycosylation of HSP90B1: during translation, associates with nascent HSP90B1 and the STT3A catalytic component of the OST-A complex and tethers them to a specialized translocon that forms a microenvironment for HSP90B1 folding (PubMed:38670073, PubMed:39509507). In the CCDC134-containing translocon, STT3A associates with the SRT pseudosubstrate motif of HSP90B1, preventing access to facultative glycosylation sites until folding is completed,

preventing hyperglycosylation and subsequent degradation of HSP90B1 (PubMed:39509507). In extracellular secreted form, promotes proliferation and activation of CD8(+) T-cells, suggesting a cytokine-like function (PubMed:25125657). May inhibit ERK and JNK signaling activity (PubMed:18087676, PubMed:23070808). May suppress cell migration and invasion activity, via its effects on ERK and JNK signaling (PubMed:23070808). May also localize in the nucleus: enhances stability of the PCAF histone acetyltransferase (HAT) complex member TADA2A and thus promotes PCAF-mediated histone acetyltransferase activity (PubMed:22644376). Has a critical role in the regulation of osteogenesis and bone development (PubMed:32181939).

Cellular Location

Endoplasmic reticulum lumen. Secreted. Cytoplasm Nucleus. Note=Mainly localizes to the endoplasmic reticulum (PubMed:39509507). Accumulates in the nucleus in response to UV irradiation (PubMed:22644376)

Tissue Location


Expressed in cervical gland, cervical squamous epithelium, endometrium, stomach, kidney distal convoluted tubule, spermatogenic cells in testis, mammary gland, liver and striated muscle (at protein level) (PubMed:18087676, PubMed:23070808). Also detected in placenta (PubMed:18087676). Highest expression in testis relative to other tissues (PubMed:18087676). Detected in T cells and dendritic cells; highly expressed in activated CD8(+) T cells, and also expressed at lower levels in CD4(+) T cells (PubMed:25125657)

CCDC134 Antibody - C-terminal region - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

CCDC134 Antibody - C-terminal region - Images



Host: Rabbit
Target Name: CCDC134
Sample Tissue: Fetal Kidney lysates
Antibody Dilution: 1.0µg/ml

CCDC134 Antibody - C-terminal region - References

Collins J.E.,et al.Genome Biol. 5:R84.1-R84.11(2004).
Ota T.,et al.Nat. Genet. 36:40-45(2004).
Dunham I.,et al.Nature 402:489-495(1999).
Burkard T.R.,et al.BMC Syst. Biol. 5:17-17(2011).